At a glance
- Originator Nippon Organon
- Class Anti-ischaemics; Antiarrhythmics; Benzoxazines; Cardiotonics; Guanidines; Small molecules
- Mechanism of Action Sodium hydrogen antiporter inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Arrhythmias; Ischaemic heart disorders
Most Recent Events
- 16 Nov 1999 Kanebo's pharmaceutical business has been merged with Organon's Japanese operations to form Nippon Organon
- 16 Nov 1999 A preclinical study has been added to the Ischaemic Heart Disease pharmacodynamics section
- 09 Jun 1999 A preclinical study has been added to the Arrhythmias pharmacodynamics section